Navigation

liotrix (Thyrolar)

 

Classes: Thyroid Products

Dosing and uses of Thyrolar (liotrix)

 

Adult dosage forms and strengths

Each 60 mg tablet will replace approximately 60-65 mg (1 grain) of desicated thyroid

Liothyronine sodium (T3) is approximately 4 times as potent as levothyroxine (T4)

tablet, T3/T4

  • Thyrolar 1/4 (15mg): 3.1/12.5mcg
  • Thyrolar 1/2 (30mg): 6.25/25mcg
  • Thyrolar 1 (60mg): 12.5/50mcg
  • Thyrolar 2 (120mg): 25/100mcg
  • Thyrolar 3 (180mg): 37.5/150mcg

 

Hypothyroidism

1 tab of Thyrolar 1/2 daily; follow with increments of 1 tab of Thyrolar 1/4 q2-3wk

Lower starting dose of 1 tab recommended in long-standing myxedema, especially if cardiovascular impairment suspected where extreme caution recommended

Maintenance: 1 tab Thyrolar 1 to 1 tab Thyrolar 2 per day; failure to respond to tab Thyrolar 3 may suggest lack of compliance or malabsorption

Adjust dose within the first 4 weeks of therapy after proper clinical laboratory evaluations where serum levels of T4 bound and free TSH are measured

Administer before breakfast

 

Pediatric dosage forms and strengths

Each 60 mg tablet will replace approximately 60-65 mg (1 grain) of desicated thyroid

Liothyronine sodium (T3) is approximately 4 times as potent as levothyroxine (T4)

tablet, T3/T4

  • Thyrolar 1/4 (15mg): 3.1/12.5mcg
  • Thyrolar 1/2 (30mg): 6.25/25mcg
  • Thyrolar 1 (60mg): 12.5/50mcg
  • Thyrolar 2 (120mg): 25/100mcg
  • Thyrolar 3 (180mg): 37.5/150mcg

 

Congenital Hypothyroidism

0-6 months: 3.1/12.5 to 6.25/25 PO;

6-12 months: 6.25/25 to 9.35/37.5 PO;

1-5 years: 9.35/37.5-12.5/50 mcg PO;

6-12 years: 12.5/50-18.75/75 mcg PO;

>12 years: >18.75/75 mcg PO;

Administration: Before breakfast

 

Thyrolar (liotrix) adverse (side) effects

Frequency not defined

Arrhythmias

Increased blood pressure

Chest pain

Palpitation

Anxiety

Headache

Urticaria

Changes in menstrual cycle

Insomnia

Hyperhydrosis pruritus

Tachycardia

Nervousness

Tremor

Cramps

Increased appetite

Weight loss

Diarrhea

 

Warnings

Black box warnings

Thyroid hormones, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss

In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

 

Contraindications

Hypersensitivity to thyroid hormone

Acute MI uncomplicated by hypothyroidism, untreated thyrotoxicosis, untreated adrenal insufficiency

Treatment of obesity

 

Cautions

Caution in angina, cardiovascular disease, HTN, endocrine disorders, elderly

Use caution in patients with adrenal insufficiency (symptoms may become exagerated or aggravated)

Euthroid withdrawn from U.S. market

Use caution in patients with myxedema (symptoms may become exagerated or aggravated)

No advantage over levothyroxine & may do more harm (T3 overdosage) than good

Not for the treatment of female infertility in euthyroid patients

 

Pregnancy and lactation

Pregnancy category: A

Lactation: Small amount excreted into breast milk, use caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Thyrolar (liotrix)

 

Mechanism of action

Natural thyroid hormone; increases basal metabolic rate, increases utilization and mobilization of glycogen store, promotes gluconeogenesis

 

Pharmacokinetics

Half-Life (T4): 6-7 days (euthyroid); 3-4 days (hyperthyroid); 9-10 days (hypothyroid)

Half-life (T3): 2.5 days

Onset: 48 hr

Absorption: 40-80% (T4); 95% (T3)

Max effect: 8-10 days

Peak Plasma Time: 12-48 hr

Bioavailability: 50-95%

Protein Bound: 99% (T4)

Metabolism: Liver, also in kidney & intestinal walls

Metabolites: Triiodothyronine (T3)

Excretion: Urine (major), feces